Table 3.
Changes in best-corrected visual acuity, central choroidal thickness, and central subfield macular thickness after the initial switch to intravitreal faricimab by treatment subgroup
| Parameters | Prior treatment | |||||
|---|---|---|---|---|---|---|
| Brolucizumab (n = 54) | Aflibercept (n = 26) | |||||
| Pre-IVF | Post-IVF | Difference (P-value) | Pre-IVF | Post-IVF | Difference (P-value) | |
| LogMAR BCVA (SD)a | 0.36 (0.36) | 0.36 (0.38) | 0.0034 (0.83) | 0.30 (0.39) | 0.34 (0.44) | 0.042 (0.19) |
| CST, µm (SD)a | 248 (78) | 245 (91) | − 3.1 (0.73) | 231 (57) | 238 (61) | 6.7 (0.62) |
| CCT, µm (SD)a | 181 (79) | 172 (78) | − 8.7 (< 0.0001) | 207 (128) | 194 (128) | − 13.1 (< 0.0001) |
aPaired t-test